miRNA Therapeutics
Asuragen recently formed a new company,
Mirna Therapeutics, Inc., a wholly-owned subsidiary of Asuragen, Inc., to
advance the pioneering work in miRNA therapeutics initiated by scientists at Asuragen.
In keeping with the tradition of its parent company, Mirna therapeutics employs
world class researchers with experience in oncology, molecular biology, biotechnology
and medicine. Mirna’s mission is the development of therapies that address various
human diseases with significant unmet medical needs. Mirna’s most advanced programs
are directed toward oncology and include therapies for prostate cancer, non-small
cell lung cancer and acute myeloid leukemia. Mirna Therapeutics has exclusive access
to Asuragen’s therapeutically-relevant intellectual property, and will exploit Asuragen’s
long-standing collaborations with top universities and biopharmaceutical companies.
Featuring world-class research capabilities, a strong understanding of miRNA and
cancer biology, and an expansive IP portfolio, Mirna is well-positioned to capitalize
on the emerging field of miRNA-based therapeutics.